ASX ANNOUNCEMENT

FebriDx® U.S. Rollout and Reimbursement Update - Amended

MELBOURNE, Australia (18 May 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, appends an update to the announcement released earlier today. In the appended version, the date reference in the final bullet of the highlights, and accompanying paragraph have been corrected to note that the foundations are being build "built out ahead of the 2026/27 U.S. flu season".

Please find the amended announcement attached.

ASX ANNOUNCEMENT

FebriDx® U.S. Rollout and Reimbursement Update

Key Highlights

- **Initial reimbursement signals highly encouraging, with >90% of submitted claims being paid and average payments above the Medicare fee schedule rate of US$41.38 per test.**
- **Lumos' eight additional pilot sites with new urgent care operators/chains, together with additional prospects, is progressing favourably through evaluation and implementation**
- **Early U.S. commercial rollout progressing, with FebriDx® now in routine use across 44 WellStreet urgent care clinics**
- **Foundations being built out ahead of the 2026/27 U.S. flu season, with customer onboarding, pilot evaluations and reimbursement pathways maturing following the recent FDA CLIA waiver.**

MELBOURNE, Australia (18 May 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased provide an update on the ongoing progress of the FebriDx® rollout in the U.S. market following the recent FDA CLIA waiver clearance for the test (ASX: 27 March 2026).

Since securing CLIA waiver, Lumos has been focused on building the commercial foundations for broader adoption ahead of the 2026/27 U.S. flu season. While respiratory testing volumes are seasonally lower in the U.S. at this time of year (during spring and summer), this period is important for creating market awareness, onboarding customers, progressing pilot evaluations and ensuring reimbursement pathways are functioning as expected in CLIA-waived settings.

Commercial progress

Commercialisation activities across the urgent care market continue to advance. As previously disclosed (ASX: 14 April 2026), WellStreet Urgent Care is now routinely using FebriDx® across 44 clinics within its network of approximately 165 locations, providing an important early implementation reference point.

In parallel, Lumos is actively progressing numerous additional pilot sites with new urgent care operators/chains. The 8 urgent care chains run by new operator ownership groups (ASX: Q3 FY26 Presentation 21 April 2026) are progressing favourably in their evaluation and implementation of FebriDx, an encouraging early sign as Lumos builds its installed base ahead of the next flu season. Lumos continues to actively build out its broader sales pipeline across urgent care operators across the greater US market and the company will continue to provide updates as these opportunities progress.

Reimbursement progress

A key component of successful U.S. commercialisation is demonstrating that providers can receive reimbursement for FebriDx® use. FebriDx® has a dedicated Proprietary Laboratory Analyses (PLA) code, 0442U, with a Medicare fee schedule rate of US$41.38 per test, which provides an important reimbursement benchmark for providers and payers.

Lumos is receiving regular reimbursement updates through its consultants, PRO-spectus and AcuityMD, and is now beginning to see early data from sites using FebriDx®. While this dataset is still in its infancy and not yet statistically significant, the initial indicators are encouraging:

- >90% of submitted claims are being reimbursed.
- The average payment among paying accounts is above the Medicare fee schedule rate of US$41.38.
- These early signs suggest reimbursement performance is tracking positively in the initial stages of launch, supporting Lumos' strategy of driving adoption in urgent care and primary care settings where providers need both clinical confidence and economic clarity.

Lumos CEO Doug Ward said: *"Securing CLIA waiver was a major step forward, but successful commercialisation also depends on showing that providers can implement FebriDx® routinely and receive payment for its use.*

While these reimbursement datasets are still in their infancy and not yet statistically significant, we are very pleased with the initial signals. They support the view that FebriDx® can be embedded into routine workflows in urgent care and primary care, particularly as providers prepare for the next flu season."

Next steps

Lumos will continue to support customers with reimbursement education and claims optimisation as payer pathways and site workflows mature.

For ASX communications, news and other regular company updates, investors are encouraged to subscribe for email alerts from Lumos. To do so, please visit: https://lumosdiagnostics.com/invest.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

[1]Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database). Precision Business Insights, US Acute Respiratory Infections, 2024.

About FebriDx®

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections after 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

Recent CLIA waiver clearance expands the applicability of FebriDx® to over 300,000 locations across the US[1], covering a broad range of healthcare settings, spanning primary care physician offices, urgent care clinics, retail health & pharmacy clinics and community health centres that hold a Certificate of Waiver. This milestone marks a significant commercial achievement for Lumos, positioning FebriDx® to reach tens of millions more patients without the need for complex laboratory infrastructure or specialised training.

With the CLIA waiver now granted, FebriDx® can be deployed more broadly, potentially reaching 80 million patients[2] per annum in the US who present with acute respiratory infections at primary care and urgent care centres. This unlocks a US$1.0+ billion market opportunity, approximately 15 times larger than the market opportunity available to the Company under the previous moderate-complexity classification.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:
Tom Trezona – Australia
H^CK Acting Managing Director
tom@hck.digital
+61 411 235 692

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598